Aptose Biosciences Inc - ESG Rating & Company Profile powered by AI
Complete ESG analysis of Aptose Biosciences Inc are reached by signing in. The webpage is a zero-cost ESG assessment for Aptose Biosciences Inc. Jump to the bottom of the page for potential risks for Aptose Biosciences Inc based on industry, location and size.
Aptose Biosciences Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.4; made up of an environmental score of 5.3, social score of 8.0 and governance score of 6.0.
6.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 389 | WuXi Biologics (Cayman) Inc | 6.6 | High |
| 401 | Oxford Cannabinoid Technologies Holdings PLC | 6.5 | High |
| 402 | Aptose Biosciences Inc | 6.4 | High |
| 402 | Capricor Therapeutics Inc | 6.4 | High |
| 402 | Alembic Pharmaceuticals Ltd | 6.4 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Aptose Biosciences Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Aptose Biosciences Inc report the average age of the workforce?
Sign up for free to unlockDoes Aptose Biosciences Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Aptose Biosciences Inc offer flexible work?
Sign up for free to unlockDoes Aptose Biosciences Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Aptose Biosciences Inc conduct supply chain audits?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Aptose Biosciences Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose water use targets?
Sign up for free to unlockDoes Aptose Biosciences Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Aptose Biosciences Inc have a product recall in the last two years?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Aptose Biosciences Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Aptose Biosciences Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose parental leave metrics?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Aptose Biosciences Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Aptose Biosciences Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Aptose Biosciences Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose its waste policy?
Sign up for free to unlockDoes Aptose Biosciences Inc report according to TCFD requirements?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose energy use targets?
Sign up for free to unlockDoes Aptose Biosciences Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Aptose Biosciences Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Aptose Biosciences Inc
These potential risks are based on the size, segment and geographies of the company.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.